Matinas BioPharma (NYSEAMERICAN:MTNB) posted its earnings results on Tuesday. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01), Fidelity Earnings reports.
Shares of NYSEAMERICAN:MTNB opened at $0.95 on Wednesday. Matinas BioPharma has a 52-week low of $0.32 and a 52-week high of $1.50.
MTNB has been the topic of several analyst reports. Roth Capital initiated coverage on shares of Matinas BioPharma in a research report on Monday, February 11th. They set a “buy” rating and a $4.75 target price on the stock. Zacks Investment Research raised shares of Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Tuesday, April 16th.
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Further Reading: Beige Book
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.